Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Development of ALL-Hematotox (ALL-HT): Predicting post CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia.
Nair MS, Silbert SK, Rejeski K, Wilson KA, Lamble AJ, Valtis YK, Yates B, Morales Arana A, Shouval R, Curran KJ, Gardner RA, Shalabi H, Annesley C, Park JH, Subklewe M, Shah NN. Nair MS, et al. Among authors: lamble aj. Blood. 2024 Nov 19:blood.2024025910. doi: 10.1182/blood.2024025910. Online ahead of print. Blood. 2024. PMID: 39561284
CRLF2-rearranged B-cell ALL with extramedullary lineage switch to AML following CD19-targeted therapy.
Silbert SK, Scanlon S, Wang HW, Yuan CM, Doverte A, Wellek J, Patel N, Braylan R, Ahlman M, Turkbey EB, Bohling SD, Chisholm KM, Oztek MA, LaLoggia M, Verma A, Shalabi H, Kovach AE, Wood BL, Lamble A, Kirsch I, Leger K, Shah NN. Silbert SK, et al. Among authors: lamble a. J Immunother Cancer. 2024 Oct 26;12(10):e009499. doi: 10.1136/jitc-2024-009499. J Immunother Cancer. 2024. PMID: 39461880 Free PMC article.
Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma.
Herrera AF, LeBlanc M, Castellino SM, Li H, Rutherford SC, Evens AM, Davison K, Punnett A, Parsons SK, Ahmed S, Casulo C, Bartlett NL, Tuscano JM, Mei MG, Hess BT, Jacobs R, Saeed H, Torka P, Hu B, Moskowitz C, Kaur S, Goyal G, Forlenza C, Doan A, Lamble A, Kumar P, Chowdhury S, Brinker B, Sharma N, Singh A, Blum KA, Perry AM, Kovach A, Hodgson D, Constine LS, Shields LK, Prica A, Dillon H, Little RF, Shipp MA, Crump M, Kahl B, Leonard JP, Smith SM, Song JY, Kelly KM, Friedberg JW. Herrera AF, et al. Among authors: lamble a. N Engl J Med. 2024 Oct 17;391(15):1379-1389. doi: 10.1056/NEJMoa2405888. N Engl J Med. 2024. PMID: 39413375 Free PMC article. Clinical Trial.
Feasibility and Favorable Responses Following Investigational CAR T-Cell Therapy for Relapsed and Refractory Infant ALL.
Annesley C, Lamble AJ, Summers C, Pulsipher MA, Wayne AS, Rivers J, Huang W, Wilson A, Wu Q, Seidel KD, Mgebroff S, Brown CT, Lindgren C, Park JR, Jensen MC, Gardner RA. Annesley C, et al. Among authors: lamble aj. Blood Adv. 2024 Aug 12:bloodadvances.2024012638. doi: 10.1182/bloodadvances.2024012638. Online ahead of print. Blood Adv. 2024. PMID: 39133891
How I treat postimmunotherapy relapsed B-ALL.
Lamble AJ, Kovach AE, Shah NN. Lamble AJ, et al. Blood. 2025 Jan 2;145(1):64-74. doi: 10.1182/blood.2024024517. Blood. 2025. PMID: 39046821 Review.
Drug-regulated CD33-targeted CAR T cells control AML using clinically optimized rapamycin dosing.
Appelbaum J, Price AE, Oda K, Zhang J, Leung WH, Tampella G, Xia D, So PP, Hilton SK, Evandy C, Sarkar S, Martin U, Krostag AR, Leonardi M, Zak DE, Logan R, Lewis P, Franke-Welch S, Ngwenyama N, Fitzgerald M, Tulberg N, Rawlings-Rhea S, Gardner RA, Jones K, Sanabria A, Crago W, Timmer J, Hollands A, Eckelman B, Bilic S, Woodworth J, Lamble A, Gregory PD, Jarjour J, Pogson M, Gustafson JA, Astrakhan A, Jensen MC. Appelbaum J, et al. Among authors: lamble a. J Clin Invest. 2024 Mar 19;134(9):e162593. doi: 10.1172/JCI162593. J Clin Invest. 2024. PMID: 38502193 Free PMC article. Clinical Trial.
Nivolumab Plus 5-Azacitidine in Pediatric Relapsed/Refractory Acute Myeloid Leukemia (AML): Phase I/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium.
Verma A, Chi YY, Malvar J, Lamble A, Chaudhury S, Agarwal A, Li HT, Liang G, Leong R, Brown PA, Kaplan J, Schafer ES, Slone T, Pauly M, Chang BH, Stieglitz E, Wayne AS, Hijiya N, Bhojwani D. Verma A, et al. Among authors: lamble a. Cancers (Basel). 2024 Jan 24;16(3):496. doi: 10.3390/cancers16030496. Cancers (Basel). 2024. PMID: 38339248 Free PMC article.
40 results